JP2025505589A - 免疫系を刺激する線維芽細胞の治療的使用 - Google Patents

免疫系を刺激する線維芽細胞の治療的使用 Download PDF

Info

Publication number
JP2025505589A
JP2025505589A JP2024546022A JP2024546022A JP2025505589A JP 2025505589 A JP2025505589 A JP 2025505589A JP 2024546022 A JP2024546022 A JP 2024546022A JP 2024546022 A JP2024546022 A JP 2024546022A JP 2025505589 A JP2025505589 A JP 2025505589A
Authority
JP
Japan
Prior art keywords
fibroblasts
activated
cells
tissue
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505589A5 (cg-RX-API-DMAC7.html
Inventor
オヒーロン、ピート
ホージャ、ハミド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrobiologics Inc
Original Assignee
Fibrobiologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrobiologics Inc filed Critical Fibrobiologics Inc
Publication of JP2025505589A publication Critical patent/JP2025505589A/ja
Publication of JP2025505589A5 publication Critical patent/JP2025505589A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2024546022A 2022-02-02 2023-02-02 免疫系を刺激する線維芽細胞の治療的使用 Pending JP2025505589A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263305973P 2022-02-02 2022-02-02
US63/305,973 2022-02-02
US202263383499P 2022-11-13 2022-11-13
US63/383,499 2022-11-13
PCT/US2023/061809 WO2023150590A2 (en) 2022-02-02 2023-02-02 Therapeutic use of fibroblasts to stimulate the immune system

Publications (2)

Publication Number Publication Date
JP2025505589A true JP2025505589A (ja) 2025-02-28
JP2025505589A5 JP2025505589A5 (cg-RX-API-DMAC7.html) 2026-02-09

Family

ID=87553049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546022A Pending JP2025505589A (ja) 2022-02-02 2023-02-02 免疫系を刺激する線維芽細胞の治療的使用

Country Status (6)

Country Link
US (1) US20250090594A1 (cg-RX-API-DMAC7.html)
EP (1) EP4472644A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505589A (cg-RX-API-DMAC7.html)
AU (1) AU2023215314A1 (cg-RX-API-DMAC7.html)
CA (1) CA3261913A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023150590A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025264574A1 (en) * 2024-06-17 2025-12-26 Fibrobiologics, Inc. Injectable thymus organoids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338953B1 (en) * 1996-09-11 2002-01-15 The General Hospital Corporation Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
US20100178700A1 (en) * 2007-05-03 2010-07-15 Australian Stem Cell Centre Ltd. Novel thymic cellular populations and uses thereof

Also Published As

Publication number Publication date
CA3261913A1 (en) 2023-08-10
WO2023150590A2 (en) 2023-08-10
WO2023150590A3 (en) 2023-09-07
EP4472644A2 (en) 2024-12-11
EP4472644A4 (en) 2026-02-25
AU2023215314A1 (en) 2024-08-15
US20250090594A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
US20240173354A1 (en) Methods of inhibiting aging and treating aging-related disorders
US12150963B2 (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
EP1261694B1 (en) Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
CN101072866A (zh) 通过施用rna改变细胞性质的方法
TW202330910A (zh) T細胞的製造方法
EP4218779B1 (en) Mesenchymal stem cells and immunogens for use in inducing acquired immunological tolerance
JP2024516172A (ja) 間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群(ards)を治療するための方法
EP3359553A1 (en) Compositions and methods for treating diabetic retinopathy
US20250090594A1 (en) Therapeutic use of fibroblasts to stimulate the immune system
JP2015000064A (ja) 造血幹細胞の増殖方法
JP2025508965A (ja) 萎縮した脾臓の再生と修復を刺激する線維芽細胞の治療的使用
US20150174222A1 (en) Modification of the immunomodulatory effects of cells
US20180333437A1 (en) Pharmaceutical composition including il-10-expressing neural stem cells for treating central nervous system disease or injury and treatment method using the same
CN115803436A (zh) 免疫原性降低的新型移植细胞
JP2022513490A (ja) 遺伝子編集線維芽細胞の治療的使用
CN119464288B (zh) 一种环状rna、过表达载体、构建方法、检测引物和应用
WO2015153880A2 (en) Modulation of hotair and adipogenesis
EP2830639B1 (en) Methods and compositions using fgf-8 to enhance cardiac regeneration and attenuate adverse cardiac remodeling
JP2020132592A (ja) 生体内でドパミン神経細胞を保護する方法
US20240400984A1 (en) Treatment of Neuronal Absence Disease by Transdifferentiating Treatment
WO2021151029A1 (en) Therapeutic exosomes and method of producing them
HK1240598B (en) Peptide for inducing regeneration of tissue and use thereof
WO2006126263A1 (ja) Vhlペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260130